{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '99', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'are considered clinically significant by the investigator (eg, SAE or AE or dose', 'modification), then the results must be recorded in the appropriate CRF (eg, SLAB).', 'For any laboratory tests with values considered clinically significantly abnormal', 'during participation in the study or within 30 days after the last dose of study', 'intervention, every attempt should be made to perform repeat assessments until the', 'values return to normal or baseline or if a new baseline is established as determined', 'by the investigator.', '8.3.5.2 Pregnancy Test', 'All women who are being considered for participation in the study, and who are not', 'surgically sterilized or postmenopausal, must be tested for pregnancy within 24 hours of the', 'first dose of study intervention. If a urine test is positive or not evaluable, a serum test will be', 'required. Participants must be excluded/discontinued from the study in the event of a positive', 'test result. Repeated pregnancy test (such as monthly testing) may be conducted if required', 'by local regulations.', '8.4', 'Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable', 'Safety Events', 'The definitions of an AE or SAE, as well as the method of recording, evaluating, and', 'assessing causality of AE and SAE and the procedures for completing and transmitting AE,', 'SAE, and other reportable safety event reports can be found in Appendix 3.', 'Progression of the cancer under study is not considered an AE as described in Section 8.4.6', 'and Appendix 3.', 'Adverse events, SAEs, and other reportable safety events will be reported by the participant', \"(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized\", 'representative).', 'The investigator and any designees are responsible for detecting, documenting, and reporting', 'events that meet the definition of an AE or SAE as well as other reportable safety events.', 'Investigators remain responsible for following up AEs, SAEs, and other reportable safety', 'events for outcome according to Section 8.4.3.', 'The investigator, who is a qualified physician, will assess events that meet the definition of', 'an AE or SAE as well as other reportable safety events with respect to seriousness,', 'intensity/toxicity and causality.', '8.4.1', 'Time Period and Frequency for Collecting AE, SAE, and Other Reportable', 'Safety Event Information', 'All AEs, SAEs, and other reportable safety events that occur after the participant provides', 'documented informed consent but before intervention allocation/randomization must be', 'reported by the investigator if the participant is receiving placebo run-in or other run-in', 'treatment, if the event cause the participant to be excluded from the study, or is the result of a', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '100', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'protocol-specified intervention, including but not limited to washout or discontinuation of', 'usual therapy, diet, or a procedure.', 'All AEs from the time of intervention allocation/randomization through 30 days', 'following cessation of study intervention must be reported by the investigator.', 'All AEs meeting serious criteria, from the time of intervention', 'allocation/randomization through 90 days following cessation of study intervention or', '30 days following cessation of study intervention if the participant initiates new', 'anticancer therapy, whichever is earlier, must be reported by the investigator.', 'All pregnancies and exposure during breastfeeding, from the time of treatment', 'allocation/randomization through 120 days following pembrolizumab/placebo or 30', 'days following cessation of lenvatinib/placebo, whichever occurs last, must be', 'reported by the investigator. If the participant initiates new anticancer therapy', 'following discontinuation of study intervention, the time period for reporting', 'pregnancies and exposure during breastfeeding is reduced to 30 days following', 'cessation of study intervention.', 'Exception: A positive pregnancy test at the time of initial screening is not a reportable', 'event unless the participant has received study intervention.', 'Additionally, any SAE brought to the attention of an investigator at any time outside', 'the time period specified above must be reported immediately to the Sponsor if the', 'event is considered related to study intervention.', 'Investigators are not obligated to actively seek AEs or SAEs or other reportable safety events', 'in former study participants. However, if the investigator learns of any SAE, including a', 'death, at any time after a participant has been discharged from the study, and he/she', 'considers the event to be reasonably related to the study intervention or study participation,', 'the investigator must promptly notify the Sponsor.', 'All initial and follow-up AEs, SAEs, and other reportable safety events will be recorded and', 'reported to the Sponsor or designee within the time frames as indicated in Table 6.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}